Alcon Inc. (ALC)
$
86.35
+0.97 (1.12%)
Key metrics
Financial statements
Free cash flow per share
3.4748
Market cap
42.7 Billion
Price to sales ratio
4.2966
Debt to equity
0.2361
Current ratio
2.7012
Income quality
2.7426
Average inventory
2.3 Billion
ROE
0.0695
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
The financial data pertains to the fiscal year 2024. During this period, the company incurred an income tax expense of $238,000,000.00 indicating its tax obligations. The net total of other income and expenses is -$157,000,000.00 reflecting non-core financial activities. Furthermore, the gross profit ratio is 0.56 reflecting the efficiency of the company's production and sales operations. The net income ratio is 0.10 reflecting the company's profitability margin. Alcon Inc. is dedicated to advancing eye care through its Surgical and Vision Care segments, offering a comprehensive range of products such as intraocular lenses, surgical equipment, diagnostic tools, contact lenses, and ocular health solutions. Founded in 1945 and headquartered in Geneva, Switzerland, Alcon is committed to innovation and quality, ensuring that healthcare professionals and patients benefit from its advanced technologies and eye care solutions. The stock is reasonably priced at $86.35 appealing to a broad range of investors. With a mid-range market capitalization of $42,708,710,000.00 the company is a steady performer. Additionally, the stock has an average trading volume of 1,693,285.00 indicating moderate liquidity. Alcon Inc. is a key player in the Medical - Instruments & Supplies industry, contributing significantly to the overall market landscape. It belongs to the Healthcare sector, driving innovation and growth. The company’s strategic focus on enhancing vision care and developing advanced surgical solutions positions it as a vital contributor in the eye care market, meeting the diverse needs of eye care professionals and patients worldwide.
Is Alcon Inc. (ALC) a good investment?
Investing in Alcon Inc. (ALC) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B, with a Bearish outlook. Always conduct your own research before investing.
What is Alcon Inc. (ALC)'s stock forecast?
Analysts predict Alcon Inc. stock to fluctuate between $80.48 (low) and $101.10 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Alcon Inc.'s market capitalization?
As of 2025-05-29, Alcon Inc.'s market cap is $42,708,710,000, based on 494,600,000 outstanding shares.
How does Alcon Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Alcon Inc. has a Lower Market-Cap, indicating a difference in performance.
Does Alcon Inc. pay dividends?
Alcon Inc. pays dividends. The current dividend yield is 0.36%, with a payout of $0.33 per share.
How can I buy Alcon Inc. (ALC) stock?
To buy Alcon Inc. (ALC) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ALC. Place an order (Market, Limit, etc.).
What is the best time to invest in Alcon Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Alcon Inc. perform in the last earnings report?
Revenue: $9,911,000,000 | EPS: $2.06 | Growth: 4.04%.
Where can I find Alcon Inc.'s investor relations reports?
Visit https://www.alcon.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Alcon Inc.?
You can explore historical data from here
What is the all-time high and low for Alcon Inc. stock?
All-time high: $101.10 (2024-09-12) | All-time low: $55.21 (2022-10-13).
What are the key trends affecting Alcon Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
FDA approves ALC's TRYPTYR, a new dry eye treatment with rapid tear production. The approval is supported by strong Phase 3 trial results.
reuters.com
Eye-care drugmaker Alcon said on Wednesday that the U.S. Food and Drug Administration has approved its treatment for dry eye disease (DED).
businesswire.com
GENEVA--(BUSINESS WIRE)--Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease.
globenewswire.com
The Turkish Contact Lens Market, valued at USD 55.15 Million in 2024, is set to reach USD 91.08 Million by 2030, at a CAGR of 8.68%. Growth is driven by rising vision correction awareness and demand for cosmetic lenses. The Turkish Contact Lens Market, valued at USD 55.15 Million in 2024, is set to reach USD 91.08 Million by 2030, at a CAGR of 8.68%. Growth is driven by rising vision correction awareness and demand for cosmetic lenses.
zacks.com
ALC ends the first quarter of 2025 on a disappointing note.
zacks.com
The headline numbers for Alcon (ALC) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
businesswire.com
GENEVA--(BUSINESS WIRE)--Alcon Reports First-Quarter 2025 Results and Launches Transformational Change in Ophthalmic Surgery with Unity VCS.
businesswire.com
GENEVA--(BUSINESS WIRE)--Alcon Announces Results of 2025 Annual General Meeting.
businesswire.com
ST. CATHARINES, Ontario--(BUSINESS WIRE)-- #yourmarinecarrierofchoice--Algoma Central Corporation (TSX: ALC) ("Algoma", the "Company") today reported its results for the three months ended March 31, 2025. Algoma reported revenues of $107,201, compared to revenues of $109,214 in 2024. Net loss for 2025 was $23,280 compared to a net loss of $17,253 for the same period in 2024. Due to the closing of the canal system and the winter weather conditions on the Great Lakes – St. Lawrence Seaway, the majority of the Domestic Dry-Bu.
businesswire.com
SAINT JOHN, New Brunswick--(BUSINESS WIRE)-- #yourmarinecarrierofchoice--Irving Oil and Algoma Central Corporation (“Algoma”) (TSX: ALC) welcomed the first of two new product tankers into Saint John Harbour today. The vessels will service Canada's largest refinery with deliveries to ports in Atlantic Canada and the U.S. East Coast. The vessels represent a total investment of $127 million by Algoma in partnership with Irving Oil. The Algoma East Coast and the Algoma Acadian – the latter of which will arrive later this sprin.
See all news
